期刊文献+

KDEL修饰的HSV-2CD8^+T细胞表位促进CTL效应的研究 被引量:2

CTL Epitopes Modified by KDEL and Recognized by CD8^(+ )T Lymphocytes to Herpes Simplex Virus Type 2 Improve CTL Effect
在线阅读 下载PDF
导出
摘要 目的:研究赖氨酸天冬氨酸谷氨酸亮氨酸(Lys-Asp-GluLeu,KDEL)修饰的2型单纯疱疹病毒(herpessimplexvirustype2,HSV2)CD8+T细胞表位促进细胞毒T淋巴细胞(cytotoxicityTlymphocyte,CTL)效应。方法:将雄性C57BL/6小鼠随机分为5组,每组5只,用各抗原肽免疫C57BL/6小鼠,采用3HTdR掺入法检测淋巴细胞增殖反应、标准4h51Cr释放试验检测CD8+T细胞特异性CTL效应,观察HSV2CD8+T细胞表位(SSIEFARL,S1)、KDEL修饰的HSV-2CD8+T细胞表位(SSIEFARL-KDEL,S1-KDEL)、4拷贝串联的CTL表位[(SSIEFARL)4,S4]及KDEL修饰的串联CTL表位[(SSIEFARL)4KDEL,S4-KDEL]的特异性细胞免疫应答。结果:3HTdR掺入试验中,S4组和S4KDEL组cpm值显著高于对照组和S1组、S1KDEL组(P<0.05);S4KDEL组的cpm值显著高于S4组(P<0.05);S1组和S1KDEL组与对照组比较,差异无显著性(P>0.05);S1组与S1KDEL组比较,cmp值亦无显著性差异(P>0.05)。以S1致敏的EL4细胞为靶细胞的杀伤实验中,S4和S4KDEL组诱导的CTL活性明显高于对照组、S1组及S1KDEL组(P<0.05);S4KDEL组诱导的CTL活性明显高于S4组(P<0.05),S1组和S1KDEL组与对照组比较,差异无显著性(P>0.05);S1组与S1KDEL组比较,差异亦无显著性(P>0.05);以EL4细胞为靶细胞的实验中,实验组的杀伤率均在10%以下,与对照组? Objective: To study the improvement of CTL effect by CTL epitopes which are modified by KDEL and recognized by CD8^(+ )T lymphocytes to herpes simplex virus type 2. Methods: Observations were made on the specific immune response induced by the CD8^(+ ) CTL epitopes(SSIEFARL, S1), the CD8^(+ ) CTL epitopes modified by KDEL(SSIEFARL-KDEL, S1-KDEL), the tandem four copies CD8^(+ ) CTL epitopes[(SSIEFARL)_(4), S4] and the tandem four copies CD8^(+ ) CTL epitopes modified by KDEL[(SSIEFARL)_(4)-KDEL, S4-KDEL], 25 male C57BL/6 mouse were randomly divided into 5 group, 5 mice per group, respectively immunized with istonic Na chloride, S1, S1-KDEL, S4 and S4-KDEL. Lymphocyte proliferation was detected by ^(3)H-TdR and the CTL effect induced by CTL epitopes in vivo was detected by ^(51)Cr. Results: In the ^(3)H-TdR test, compared with the control, the group S1 and group S1-KDEL, the cpm values of Group S4 and Group S4-KDEL were markedly higher(P<(0.05))and the cpm value of Group S4-KDEL was significantly higher than Group S4(P<(0.05)), but the cpm values of Group S1 and Group S1-KDEL were not significantly different from the control(P>(0.05) ), nor was that of Group S1 from Group S1-KDEL(P>(0.05)). In the experiment in which the EL4 cells sensitized by S1 were attacked as target cells, the CTL activities induced in Group S4 and Group S4-KDEL were markedly higher(P<(0.05)) compared with the control, Group S1 and Group S1-KDEL, and that induced in Group S4-KDEL was significantly higher than Group S4(P<(0.05)), but the CTL activity induced in Group S1 and Group S1-KDEL were not significantly different from the control(P>(0.05) ), nor was that induced in Group S1 from Group S1-KDEL(P>(0.05)). In the experiment in which the EL4 cells were attacked as target cells, the kill rate was below 10% in every group, not significantly different from the control. Conclusion: The tandem four copies CD8^(+ ) CTL epitopes, modified by KDEL and recognized by CD8^(+)T lymphocytes to herpes simplex virus type 2, can improve the CTL effect. Natl J Androl,2005,11(4):252-255
出处 《中华男科学杂志》 CAS CSCD 2005年第4期252-255,共4页 National Journal of Andrology
基金 国家自然科学基金项目(30100161)
  • 相关文献

参考文献6

  • 1Meng WS, Butterfield LH. Rational design of peptide-based tumor vaccines[J]. Pharm Res, 2002, 19(7):926-932.
  • 2Machiels JP, Van Baren N, Marchand M. Peptide-based cancer vaccines [J]. Semin Oncol, 2002, 29 (5) :494-520.
  • 3Jarnum S, Kjellman C, Darabi A. A novel ER and Golgi resident member of the Leprecan family [J]. Biochem Biophys Res,2004, 317(2): 342-351.
  • 4Joseph E, Blaney Jr, Eri Nobusawa, et al. Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2confers protective immunity [J]. J Virol, 1998, 72 (12): 9567-9574.
  • 5Leclerc C, Ronco J. New approaches in vaccine development[J]. Immunol Today, 1998, 19(7):300-302.
  • 6Carbone FR, Kurts C, Bennett SR, et al. Cross-presentation: a general mechanism for CTL immunity and tolerance [J]. Immunol Today, 1998, 19(8):368-373.

同被引文献36

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部